Showing results (1-10 of 135) with videos related to
Sort By:
Pageof 14
Frontiers in Cell and Developmental Biology|June 17, 2022
Towards Immunotherapy-Induced Normalization of the Tumor MicroenvironmentVinicio Melo, Edwin Bremer, John D MartinTheranostics|February 24, 2022
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonismJuliane Medler, Kirstin Kucka, Vinicio Melo, et al.Frontiers in Immunology|November 7, 2022
Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survivalMartijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, et al.Frontiers in Immunology|August 7, 2023
EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cellsVinicio Melo, Levi Collin Nelemans, Martijn Vlaming, et al.ISRN Oncology|July 11, 2013
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapyEdwin BremerDiscovery Medicine|January 20, 2007
Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapyEdwin Bremer, Wijnand HelfrichMethods in Molecular Biology (Clifton, N.J.)|February 6, 2014
Bifunctional antibody fragment-based fusion proteins for the targeted elimination of pathogenic T-cell subsetsWijnand Helfrich, Edwin BremerFrontiers in Bioscience : a Journal and Virtual Library|May 30, 2008
EpCAM-targeted induction of apoptosisEdwin Bremer, Wijnand HelfrichMethods in Molecular Biology (Clifton, N.J.)|May 22, 2025
A Luminescence-Based Method for In Vitro Screening of Immunomodulatory Checkpoints and TherapeuticsJimena Álvarez Freile, Edwin BremerMethods in Molecular Biology (Clifton, N.J.)|November 23, 2018
Development of Bispecific Antibody Derivatives for Cancer ImmunotherapyYuan He, Wijnand Helfrich, Edwin BremerPageof 14